Tianjin Chase Sun Pharmaceutical Co.,Ltd

Shenzhen Stock Exchange 300026.SZ

Tianjin Chase Sun Pharmaceutical Co.,Ltd Current Liabilities for the year ending December 31, 2023: USD 220.41 M

Tianjin Chase Sun Pharmaceutical Co.,Ltd Current Liabilities is USD 220.41 M for the year ending December 31, 2023, a -43.20% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.
  • Tianjin Chase Sun Pharmaceutical Co.,Ltd Current Liabilities for the year ending December 31, 2022 was USD 388.06 M, a 19.80% change year over year.
  • Tianjin Chase Sun Pharmaceutical Co.,Ltd Current Liabilities for the year ending December 31, 2021 was USD 323.93 M, a -9.64% change year over year.
  • Tianjin Chase Sun Pharmaceutical Co.,Ltd Current Liabilities for the year ending December 31, 2020 was USD 358.49 M, a 102.53% change year over year.
  • Tianjin Chase Sun Pharmaceutical Co.,Ltd Current Liabilities for the year ending December 31, 2019 was USD 177.01 M, a 45.47% change year over year.
Key data
Date Current Liabilities Total Non-Current Liabilities Shareholders' Equity Long-Term Debt
Market news
Loading...
Shenzhen Stock Exchange: 300026.SZ

Tianjin Chase Sun Pharmaceutical Co.,Ltd

CEO Ms. Dan Zheng
IPO Date Oct. 30, 2009
Location China
Headquarters No. 20, Quanfa Road
Employees 5,910
Sector Health Care
Industries
Description

Tianjin Chase Sun Pharmaceutical Co.,Ltd engages in the research, development, production, and marketing of various pharmaceutical products in China. The company offers Chinese herb preparation products, medicinal granules, synthetic drugs, biotech drugs, medical apparatus, and Internet based therapy. It is also involved in the research and development of various drugs in the areas of sepsis, pulmonary hypertension, leukemia, cardiovascular and cerebrovascular diseases, arthritis, ischemic stroke, HCV, vascular disease, psychosis, and chemotherapy, as well as anesthesia drugs and immunomodulators. The company was founded in 1996 and is based in Tianjin, China.

StockViz Staff

January 15, 2025

Any question? Send us an email